Cyclical thrombocytosis, acquired von Willebrand syndrome and aggressive non-melanoma skin cancers are common in patients with Philadelphia-negative myeloproliferative neoplasms treated with hydroxyurea

References

• Michiels JJ. Acquired von Willebrand disease due to increasing platelet count can readily explain the paradox of thrombosis and bleeding in thrombocythemia. Clin Appl Thromb Hemost 1999;5: 147–151.
   PubMed Web of Science ®Google Scholar
• Randi ML, Ruzzon E, Luzzatto G, et al. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders. Haematologica 2005;90:261–262.
   PubMed Web of Science ®Google Scholar
• Dumont-Wallon G, Milpied-Homsi B, Morineau N, et al. Cutaneomucous side effects of hydroxyurea: prospective study of 27 patients. Hematologie 2006;12:262–266.
   Google Scholar
• Leo E, Krämer A, Hochhaus A, et al. Gangrene of the toes in a patient with chronic myelogenous leukemia after long-term hydroxyurea therapy. Ann Hematol 2002;81:467–469.
   PubMed Web of Science ®Google Scholar
• Antonioli E, Guglielmelli P, Pieri L, et al. Hydroxyurea-related toxicity in 3,411 patients with Ph’-negative MPN. Am J Hematol 2012;85:552–554.
   Web of Science ®Google Scholar
• Tauscher J, Siegel F, Petrides PE. Hydroxyurea induced oscillations in twelve patients with polycythemia vera. Haematologica 2010;95: 1227–1229.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Elliott MA, Kao PC, et al. Hydroxyurea-induced marked oscillations of platelet counts in patients with polycythemia vera. Blood 2000;96:1582–1584.
   PubMed Web of Science ®Google Scholar
• Schulman S, Angeras U, Bergqvist D, et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010;8:202–204.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33–45.
   PubMed Web of Science ®Google Scholar
• Westerman DA, Schwarer A, Grigg AP. Hydroxyurea induced fever and hepatitis. Int Med J 1998;28:657–659.
   Google Scholar
• Bennett M, Grunwald AJ. Hydroxyurea and periodicity in myeloproliferative disease. Eur J Haematol 2001;66:317–323.
   PubMed Web of Science ®Google Scholar
• Steensma DP, Harrison CN, Tefferi A. Hydroxyurea-associated platelet count oscillations in polycythemia vera: a report of four new cases and a review. Leuk Lymphoma 2001;42:1243–1253.
   PubMed Web of Science ®Google Scholar
• Burthem J, Chaudhry MS. Hydroxycarbamide associated platelet count oscillations in a patient with polycythaemia vera. A case report and review of the literature. Platelets 2008;19:234–235.
   PubMed Web of Science ®Google Scholar
• von Schulthess GK, Gessner U. Oscillating platelet counts in healthy individuals:experimental investigation and quantitative evaluation of thrombocytopoietic feedback control. Scand J Haematol 1986;36:473–479.
   PubMedGoogle Scholar
• Morley A, King-Smith E, Stohlman F. Oscillatory nature of hemopoiesis. In: Stohlman F editor. Hemopoietic cellular proliferation. New York: Grune & Stratton; 1970. pp 3–14.
   Google Scholar
• Sanchez-Luceros A, Meschengieser S, Woods A, et al. Acquired von Willebrand factor abnormalities in myeloproliferative disorders and other hematologic diseases: a retrospective analysis by a single institution. Haematologica 2002;87:264–270.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Smock KJ, Divgi AB. Polycythemia vera-associated acquired von Willebrand syndrome despite near-normal platelet count. Am J Hematol 2010;85:545.
   PubMed Web of Science ®Google Scholar
• Cancer Australia and Australian Institute of Health and Welfare. Non-melanoma skin cancer: general practice consultations, hospitalisation and mortality. Canberra: AIHW; 2008.
   Google Scholar
• Spivak JL, Hasselbalch H. Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders. Expert Rev Anticancer Ther 2011;11:403–414.
   PubMed Web of Science ®Google Scholar
• Pascale S, Petrucci G, Dragani A, et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 2012;119:3595–3603.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 2007;33:313–320.
   PubMed Web of Science ®Google Scholar
• Latagliata R, Spadea A, Cedrone M, et al. Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome negative myeloproliferative neoplasms: the Mister Hyde tale of a safe drug. Cancer 2012;118:404–409.
   PubMed Web of Science ®Google Scholar
• Najean Y, Rain J-D. Treatment of polycythemia vera:the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 1997;90:3370–3377.
   PubMed Web of Science ®Google Scholar